Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises—advanced chronic liver disease—to its heterogeneous clinical and biological behaviour. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Giannini, Edoardo G., Aglitti, Andrea, Borzio, Mauro, Gambato, Martina, Guarino, Maria, Iavarone, Massimo, Lai, Quirino, Levi Sandri, Giovanni Battista, Melandro, Fabio, Morisco, Filomena, Ponziani, Francesca Romana, Rendina, Maria, Russo, Francesco Paolo, Sacco, Rodolfo, Viganò, Mauro, Vitale, Alessandro, Trevisani, Franco
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896125/
https://ncbi.nlm.nih.gov/pubmed/31671581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11111689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados